Adesiyun Adebiyi Gbadebo, Ameh Nkiruka, Ozed Williams Ijeoma, Ojabo Austin, Umar Hajara.
Treatment outcome of hyperprolactinaemic infertility with carbegoline in sub Saharan Africa.
Pak J Med Sci Jan ;24(3):512-6.

ABSTARCT Objectives: Hyperprolactinaemia is a known cause of infertility. We explored the efficacy of carbegoline, the long acting dopamine agonist that was recently introduced into our medical practice. Methodology: Seventy six patients with infertility secondary to hyperprolactinaemia were studied over a period of 20 weeks each. All the patients had carbegoline twice weekly for eight weeks. Two dosage regimen were used based on the pretreatment prolactin level; less than 50ng/ml had 0.25mg twice weekly (n=58) and 50ng/ml and above 0.5mg twice weekly (n=18). Results: Normalization of prolactin level was achieved in 75 (98.7%) patients. At the end of the study period, there was resumption of menstrual flow in 10 (76.9%) of the 13 patients that were amenorrhoiec and all the 39 (100%) patients that were oligomenorrhoeic had their normal menstrual cycle restored. Resumption of ovulatory cycles occurred in 87.7% of those with anovulatory cycles. Of the 76 patients, 69 (90.8%) got pregnant during the 20 weeks study. However, out of the 69 that got pregnant, 13 (18.8%) got pregnant while on carbegoline therapy. There was no case of carbegoline resistance or discontinuation recorded in this study. Conclusion: Carbegoline is a cost effective first line therapy in the management of infertile women with hyperprolactinaemia.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com